Efgartigimod Improves Ocular Myasthenia Gravis Symptoms in Phase 3 Trial

Positive results from a late-stage clinical trial offer renewed hope for individuals living with ocular myasthenia gravis (oMG), a rare autoimmune disorder causing weakness in the muscles controlling eye movement. Treatment with Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated statistically significant improvement in patient-reported ocular symptoms compared to placebo, according to topline data released by Argenx. This development could pave the way for expanded use of the drug, currently approved for other forms of myasthenia gravis and a nerve disorder called CIDP.

Understanding Ocular Myasthenia Gravis

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease that leads to fluctuating muscle weakness. In oMG, the symptoms are primarily limited to the eye muscles, causing issues like double vision (diplopia) and drooping eyelids (ptosis). The condition arises when the immune system mistakenly attacks the connections between nerves and muscles, disrupting communication. While not life-threatening in itself, oMG can significantly impact daily life, affecting reading, driving, and overall quality of vision. The Myasthenia Gravis Foundation of America (MGFA) classifies oMG severity, with Class I representing mild symptoms.

The ADAPT OCULUS Trial: Design and Key Findings

The positive results stem from the ADAPT OCULUS trial, a randomized, double-blind, placebo-controlled phase 3 study involving 141 adults with MGFA Class I oMG across North America, Europe, and Asia-Pacific. Participants received either four weekly subcutaneous injections of Vyvgart Hytrulo or a placebo, followed by a four-week follow-up period. The primary endpoint – change in the Myasthenia Gravis Impairment Index (MGII) patient-reported outcome (PRO) ocular score from baseline to week 4 – showed a mean change of -4.04 points with Vyvgart Hytrulo versus -1.99 points with placebo. This difference of -2.05 points was statistically significant (P=.012), indicating the treatment’s effect wasn’t due to chance. Practical Neurology provides a detailed overview of the trial design.

Beyond the primary endpoint, the treatment group also experienced reductions in key ocular symptoms like diplopia and ptosis. Importantly, Vyvgart Hytrulo was well-tolerated, with a safety profile consistent with previous studies, and no new safety concerns were identified.

How Vyvgart Hytrulo Works

Vyvgart Hytrulo combines efgartigimod alfa with hyaluronidase-qvfc. Efgartigimod alfa is an antibody fragment that reduces the levels of disease-causing antibodies (specifically, anti-acetylcholine receptor antibodies) in the blood. Hyaluronidase-qvfc enhances the absorption of efgartigimod alfa when given as a subcutaneous injection. Essentially, the drug aims to rebalance the immune system and improve neuromuscular transmission. Currently, Vyvgart is approved for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), conditions where similar immune dysregulation occurs. Medscape Medical News details the mechanism of action.

What the Results Don’t Tell Us

While the ADAPT OCULUS trial results are encouraging, it’s crucial to understand their limitations. The study focused on patients with MGFA Class I oMG, meaning those with mild symptoms. The effectiveness of Vyvgart Hytrulo in individuals with more severe oMG remains unknown. The follow-up period was relatively short (four weeks). Longer-term data are needed to assess the durability of the treatment effect and potential for symptom relapse. The trial also did not investigate the impact of the treatment on quality of life beyond the MGII PRO ocular score.

The Path Forward: Regulatory Review and Potential Access

Argenx plans to submit a supplemental Biologics License Application (BLA) to the Food and Drug Administration (FDA) based on these findings, seeking to expand the drug’s label to include oMG. The FDA will review the data to determine whether the benefits of Vyvgart Hytrulo outweigh its risks for this specific patient population. If approved, this would provide a much-needed new treatment option for individuals with oMG. The review process typically takes several months. Rheumatology Advisor reports on the planned BLA submission.

What to Expect During the FDA Review

The FDA review will involve a thorough assessment of the trial data, including safety and efficacy information. The agency may also request additional data from Argenx. Public availability of the full trial results will follow the FDA review process, allowing independent researchers to scrutinize the findings.

For individuals currently managing oMG, it’s important to continue working closely with their neurologists and adhering to their prescribed treatment plans. This new data offers a potential future option, but does not change current standards of care.

Further research is also needed to better understand the underlying causes of oMG and to develop even more targeted and effective therapies. Ongoing clinical trials are exploring novel approaches to immune modulation and neuromuscular junction repair.